The Dendritic Cell Strikes Back
- PMID: 30566889
- DOI: 10.1016/j.immuni.2018.12.007
The Dendritic Cell Strikes Back
Erratum in
-
The Dendritic Cell Strikes Back.Immunity. 2019 Feb 19;50(2):533. doi: 10.1016/j.immuni.2019.01.022. Immunity. 2019. PMID: 30784580 No abstract available.
Abstract
The field of cancer immunotherapy and checkpoint blockade has focused largely on direct effects on T cells. In this issue of Immunity, Garris et al. (2018) show that the efficacy of anti-PD-1 therapy depends on a T-cell-dendritic-cell (DC) licensing loop fueled by IFN-γ and IL-12, thereby establishing a central role for DCs in promoting anti-cancer T cell immunity during checkpoint blockade.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11. Immunity. 2018. PMID: 30552023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
